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Abstract: In a previous study, we developed a prognostic prediction rule, based on nine prognostic variables, capable to 
estimate and to adjust the mortality rate of patients admitted in intensive care unit for severe community-acquired pneu-
monia. A prospective multicenter study was undertaken to evaluate the performance of this rule. Five hundred eleven pa-
tients, over a 7-year period, were studied. The ICU mortality rate was 29.0%. In the 3 initial risk classes, we observed sig-
nificantly increasing mortality rates (8.2% in class I, 22.8% in class II and 65.0% in class III) (p<0.001). Within each ini-
tial risk class, the adjustment risk score identified subclasses exhibiting significantly different mortality rates: 3.9% and 
33.3% in class I; 3.1%, 12.9% and 63.3% in class II; and 55.8% and 82.5% in class III. Compared with mortality rates 
predicted by our previous study, only a few significant differences were observed. Our results demonstrate the perform-
ance and reproductibility of this prognostic prediction rule. 
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INTRODUCTION 
  Community-acquired pneumonia (CAP) is the most fre-
quent community-acquired infection requiring intensive care 
unit (ICU) admission [1]. Approximately 10% of hospital-
ized patients with CAP require admission to the ICU [2]. 
Despite advances in supportive measures and updated guide-
lines for antimicrobial treatment, mortality associated with 
severe CAP remains high, around 20-30% [3-6]. 
  As demonstrated by several multivariate analyses, prog-
nosis of severe CAP depends on the baseline characteristics 
of patients, on the initial severity of pneumonia and on the 
evolution during ICU stay [7-9]. Taking into account these 
results, we developed in a previous work a prognostic pre-
diction rule based on two successive steps: an initial score, 
based on clinical and radiological data collected at presenta-
tion, estimated ICU outcome early after ICU admission. A 
second score, taking into account the complications occur-
ring during ICU stay, adjusted the final ICU prognosis [3]. 
  Our goal was to evaluate, in a prospective multicenter 
study, the performance of this prognostic prediction rule for 
patients admitted into ICU for severe CAP. 
PATIENTS AND METHODS 
Selection of Cases 
  From January 1996 to December 2003, we prospectively 
enrolled, in  the  validation population,  patients  admitted  to 
five ICUs with a diagnosis of severe CAP. The study sites and 
the years of data collection were Tourcoing  General  Hospital 
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(16-bed ICU affiliated with the Faculté de Médecine de Lille 
and associated with an infectious diseases unit) from 1996 to 
2003, Saint Philibert Hospital (12-bed ICU affiliated with the 
Université Catholique de Lille) in 1997 and 2002, Arras Gen-
eral Hospital (10-bed ICU) from 1996 to 2002, Lens General 
Hospital (15-bed ICU) in 1996 and Valenciennes General 
Hospital (19-bed ICU) from 1997 to 2002. The ethics commit-
tee of the Lille University Medical School was informed about 
the study and raised no objections. Patient consent was not 
required for this observational study. 
  Enrolment criteria for patient inclusion and exclusion were 
those used in our previous study, based on a development 
population including 472 patients [3]. CAP was defined by the 
following criteria observed at initial presentation or occurring 
within 48h following hospitalization [10]: presence of a new 
radiographic pulmonary infiltrate and acute onset of at least 
one "major" (cough, sputum production, fever) or two "minor" 
(dyspnea, pleuretic chest pain, altered mental status, pulmo-
nary consolidation on physical examination, total leukocyte 
count greater than 12.000/mm
3) clinical or biological findings 
suggestive of pneumonia. Patients coming from nursing home 
or hospitalized within 30 days prior to developing pneumonia 
or hospitalized > 48h in general medical wards before ICU 
admission or with a known positive HIV test or with a diagno-
sis of AIDS were excluded. Finally, patients with Do-Not-
Resuscitate or Do-Not-Intubate orders were not included. 
Data Collection and Determination of the Prognostic 
Prediction Rule 
 Fig.  (1) details the prognostic prediction rule with an 
initial classification of patients, on ICU admission, in 3 ini-
tial risk classes according to the initial risk score, and the 
stratification, in each initial risk class, in different subclasses 
according to the adjustment risk score. 68    The Open Respiratory Medicine Journal, 2008, Volume 2  Leroy et al. 
Fig. (1). Prognostic prediction rule. 
  Within 24h of ICU admission, all patients underwent 
clinical, biological and radiologic evaluation aiming to de-
termine main characteristics of patients. These characteristics 
were used to determine an initial mortality risk score [3]. 
This score is based on six independent predictors of mortal-
ity. Predictors and their point scoring system are age > 40 
years (+1 point), anticipated death within 5 years (+1 point), 
nonaspiration pneumonia (+1 point), chest radiograph in-
volvement > 1 lobe (+1 point), acute respiratory failure re-
quiring invasive mechanical ventilation (+1 point) and septic 
shock (+3 points). In adding the points, we obtain the initial 
risk score. According to its value, each patient is included in 
one of the three initial risk classes: Class I = score between 0 
and 2; Class II = score between 3 and 5; Class III = score 
between 6 and the maximal value 8. 
  During ICU stay, all complications occurring beyond the 
24 hours following the admission were recorded. An adjust-
ment risk score was determined, for each patient, according 
to the occurrence or non occurrence of complications [3]. 
This score is based on 3 independent predictors of mortality. 
The predictors and their point scoring system are hospital-
acquired lower respiratory tract (HA-LRT) superinfections 
(+ 1 point), non-specific complications (+ 2 points) and sep-
sis-related complications (+ 4 points). This score varies be-
tween 0 point (no complication) and 7 points (occurrence of 
the 3 different complications). This score allows to precise 
the final prognosis in each initial risk class in distinguishing 
in each of them 2 or 3 different subclasses with adjusted risk, 
as follows: in class I, two subclasses are distinguished ac-
cording to an adjustment risk score < 2 or > 2; in class II, 3 
subclasses are distinguished according to a score = 0, > 0 and 
< 2 or > 2; in class III, two subclasses are distinguished ac-
cording to an adjustment risk score < 2 or > 2. 
  Patients were followed until discharge from the ICU or 
death in ICU. 
  In each ICU and for each enrolled patient, a physician 
collected data using a standardized data collection sheet, 
when the patient was discharged from the ICU or when the 
patient died. All sheets were centralized by two physicians of 
our group (OL and DM) who calculated the score. All re-
corded data were analyzed by a biostatistician (PD). 
Definitions 
  The underlying clinical conditions were classified ac-
cording to the criteria proposed by McCabe and Jackson [11] 
in 3 categories: non fatal, ultimately fatal and rapidly fatal. 
Patients included in the category ultimately or rapidly fatal 
were considered as having an anticipated death within 5 
years. Septic shock was defined by usual criteria [12, 13]; 
hypotension is defined by a systolic blood pressure < 90 mm 
Hg or its decrease by at least 40 mm Hg from baseline a 
mean arterial pressure or a mean arterial pressure < 40 
mmHg, in the absence of other causes for hypotension, per-
sisting despite adequate volume replacement. The need for 
invasive mechanical ventilation within 12h following ICU 
admission defined initial acute respiratory failure. Diagnosis 
of aspiration was retained in patients with either witnessed 
aspiration or risk factors for aspiration (altered mental status, 
abnormal gag reflex of swallowing mechanism, intestinal 
obstruction) and suggestive chest X-ray infiltrates [14]. 
  Among complications occurring during the patient's stay 
in the ICU, we distinguished 3 groups: sepsis-related com-
plications included events clearly related to CAP that were 
not present within the 24 hours following ICU admission. 
These events could be a septic shock, an acute respiratory 
distress syndrome (ARDS), a multiple organ failure (MOF) 
or a diffusion of pulmonary infection (i.e., empyema). MOF, 
ARDS and HA-LRT were defined according to usual criteria 
[15-17]. HA-LRT superinfections included nosocomial 
bronchitis and pneumonia developing more than 48h after 
ICU admission. Nonspecific complications included ICU-
related complications (i.e., upper gastrointestinal bleeding, 
catheter-related infection, deep venous thrombosis and pul-
monary embolism) and complications attributed solely to 
underlying medical conditions. 
Statistical Analysis 
  To evaluate the performance of this prognostic prediction 
rule in the validation population, we determined its ability to 
stratify patients into classes and subclasses with statistically 
significant different observed mortality rates. For this pur-
pose, we compared the mortality rates observed across the 
three initial risk classes and, within each initial risk class, 
across the different adjusted risk subclasses. 
  To evaluate the reproducibility of the rule, we compared, 
across all risk classes and subclasses, the mortality rates ob-
served in the validation population to those predicted (ob-
served mortality rates in the development population upon 
elaboration of the rule). 
  All bivariate comparisons were performed by the 
2 test 
or the Fisher’s exact test when 
2 test was not appropriate. In 
all instances, p levels < 0.05 were considered significant. 
RESULTS 
  The validation population consisted of 511 patients. 
There were 364 men (71.2%) and 147 women (28.8%). The 
mean age was 61.0 ± 17 years. Main patients’ characteristics 
focusing on predictors of ICU mortality are reported in Table 
1. During the ICU stay, 148 patients (29.0%) died. 
  In this population, 122, 272 and 117 patients were in-
cluded in the initial risk classes I, II and III, respectively 
(Table 2). Respective mortality rates were 8.2%, 22.8% and 
65.0% and were significantly different (p<0.001). Within 
each initial risk class, the adjustment risk score identified 
subclasses exhibiting significantly different mortality rates: 
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in class II (p<0.001) and 55.8% vs 82.5% in class III 
(p=0.004) (Table 2). 
Table 1.  Patients Characteristics in the Validation Population* 
 
Characteristics  Validation Population 
n=511 Patients 
Age > 40 yr  450 (88.1%) 
Anticipated death within 5 yr  244 (47.7%) 
Non aspiration pneumonia  408 (79.8%) 
Chest radiograph involvement > 1 lobe   224 (43.8%) 
ARF requiring immediate invasive MV  312 (61.1%) 
Septic shock  132 (25.8%) 
HA-LRT superinfections   78 (15.3%) 
Non-specific complications  152 (29.8%) 
Sepsis-related complications  119 (23.2%) 
ARF = acute respiratory failure; MV = mechanical ventilation; HA-LRT = hospital-
acquired lower respiratory tract superinfections. 
*Data are presented as No. (%). 
 
  The comparison risk class by risk class and subclass by 
subclass of observed and predicted mortality rates is reported 
in Table 3. Only two significant differences were found. 
Within the initial risk class II, the mortality rates observed in 
two of the three subclasses were significantly lower in the 
validation population than predicted by rates observed in the 
development population. 
DISCUSSION 
  Our results demonstrate the performance and reproducti-
bility of our prognostic prediction rule in the validation 
population. On ICU admission, an initial risk score classified 
patients into three classes of increasing mortality. During the 
ICU stay, an adjustment risk score identified, in each initial 
risk class, subclasses associated with significantly different 
mortality rates. Moreover, the reproducibility of the rule ap-
peared satisfying since across the 3 classes and the 7 sub-
classes, there were only two significant differences between 
mortality rates observed in the development population and 
in the validation population. 
  Numerous rules were built in order to assess the prognosis 
of CAP. In 1997, Fine and colleagues described a prediction 
rule based on 20 clinical variables [2]. Called Pneumonia Se-
verity Index, this rule categorizes patients into 5 risk classes 
with an increasing risk of 30-day mortality. The major 
strength of this rule is to help physicians identify low risk pa-
tients at admission in the emergency room: patients in risk 
classes I-III can be considered potential candidates for outpa-
tient treatment. Similarly, Lim and colleagues described a 
prognostic model based on 4 “core” clinical adverse prognos-
tic factors [18]. This score, called CURB score (confusion, 
urea nitrogen, respiratory rate, blood pressure), identifies pa-
tients who do not require hospitalisation (no adverse prognos-
tic factor). A modified version of this score adds age > 65 
years as a fifth variable [19]. This CURB-65 score stratifying 
patients into 6 classes of increasing risk of mortality is taken 
into account by the 2004 update of the British Thoracic Soci-
ety pneumonia guidelines stating that patients with a CURB-
65 score <2 may be suitable for outpatient treatment [20, 21]. 
The major interest of these different prediction rules is the 
identification of patients who do not require hospitalisation for 
the treatment of their pneumonia. Their implication for the 
medical care of patients exhibiting severe CAP requiring ICU 
admission appears questionable. A recent study performed by 
Espana and colleagues evaluated the performances of these 
prognostic rules for identifying patients who will develop se-
vere CAP [22]. The authors demonstrated that these rules were 
less accurate than their prediction rule based on eight inde-
pendent predictive factors. The factors and their assigned 
points were the followings: arterial pH < 7.30 (13 points), 
systolic
 blood pressure < 90 mm Hg (11 points), respiratory 
rate > 30 breaths/min (9 points),
  PaO2 < 54 mm Hg or 
PaO2/FiO2 < 250 mm Hg (6 points), altered mental status (5 
points), blood urea nitrogen > 30 mg/dL (5 points), age > 80 
yr (5 points), and multilobar/bilateral lung involvement (5 
points). The percentages of patients developing severe pneu-
monia were fewer than 3% if the score was less than 10, 10% 
with a score of 10 to 19, 40% with a score of 20 to 29 and 
more than 50% with a score equal or higher than 30. 
  The goal of our prognostic prediction rule is quite differ-
ent from the goal of these rules. As demonstrated, the CURB 
scores and the Pneumonia Severity Index identify as early as 
the admission in emergency room both low-risk patients who 
are candidates for outpatient care and high-risk patients ex-
hibiting the highest 30-day mortality [23]. These scores are 
useful in helping physicians determine rational decisions 
about hospitalization of these patients. For example, it is 
obvious that an urgent hospitalization is needed for high-risk 
Table 2.  Stratification of Patients into Risk Classes and Subclasses in the Validation Population* 
 
Initial Risk Class   
I II  III 
Patients 122  272  117 
Deaths  10 (8.2%)  62 (22.8%)  76 (65.0%) 
Points of Adjustment Risk Score   
< 2  > 2  0  1 or 2  > 2  < 2  > 2 
Patients  104 18 131 62  79  77  40 
Deaths  4 (3.9%)  6 (33.3%)  4 (3.1%)  8 (12.9%)  50 (63.3%)  43 (55.8%)  33 (82.5%) 
*Data are presented as No. (%). 70    The Open Respiratory Medicine Journal, 2008, Volume 2  Leroy et al. 
patients and that ICU admission must be considered for 
them. Similarly, the rule developed by Espana and col-
leagues appears able to quantify the risk for development of 
severe CAP [22]. However, these rules do not specifically 
evaluate the prognosis of patients admitted into ICU for se-
vere CAP. Aujesky and colleagues enrolled 3181 patients 
admitted to an emergency department [23]. The Pneumonia 
Severity Index identified 200 patients included in the risk 
class V. Their mortality rate was 24%. The CURB score 
identified 7 patients in class 4 with a mortality rate of 43%. 
Finally, the CURB-65 score identified the same number of 
patients in class 5, with a similar mortality rate. The number 
of patients assessed as exhibiting a severe CAP was quite 
low and varied largely according to the rule since 200 pa-
tients were identified by the Pneumonia Severity Index and 
only 7 by the CURB scores. Moreover, the estimated mortal-
ity rate appeared imprecise, varying from 24% to 42% ac-
cording to the rule. The goal of our rule is not the identifica-
tion of patients exhibiting severe CAP, but the precise 
evaluation of prognosis for patients admitted into an ICU for 
severe CAP. Our prospective population included 511 pa-
tients admitted into ICU for severe CAP. The overall mortal-
ity rate was 29.0%. According to an initial risk score repre-
senting the first step of our prediction rule, we identified 3 
groups of patients exhibiting significantly different mortality 
rates varying from 8.2% to 65%. Secondly, in each of these 3 
groups, an adjustment risk score corrected this estimation 
and determined the final prognosis. 
  Recent studies suggest that some drugs administered as 
an adjunct to usual antimicrobial and supportive therapeutics 
could provide significant reduction in mortality for patients 
suffering from severe CAP. Opal and colleagues demon-
strated that drotrecogin alfa (activated) reduced the mortality 
rate associated with Streptococcus pneumoniae infection 
[24]. Likewise, analysis of subgroups from the PROWESS 
study showed that administration of this drug was associated 
with a decrease in 28-day mortality rates due to lung infec-
tion [25]. Despite these findings, numerous physicians are 
reluctant to use recombinant human activated protein C for 
all patients admitted in ICU for severe CAP. This might be 
explained by data emphasizing that drotrecogin alfa (acti-
vated) could be associated with both the absence of a benefi-
cial treatment effect and an increased incidence of serious 
bleeding complications in patients with severe sepsis who 
are at low risk of death [26]. Our prognostic prediction rule 
is able to identify, as early as ICU admission, patients with 
either a low or, conversely, a high risk of death. Thus, it 
could be used as an aid to clinicians to accurately differenti-
ate, at the beside, patients who could benefit (class III) from 
patients who might be harmed (class I) by drotrecogin alfa 
(activated) administration. 
  The apparent inability of our rule to immediately deter-
mine the outcome for all patients upon ICU admission could 
appear as a limitation. Indeed, for 50% of patients, the initial 
evaluation predicted an intermediate or an indeterminate 
outcome with a mortality rate similar to the overall mortality 
rate. The final outcome depended mainly on the occurrence 
or non-occurrence of complications during the ICU stay. 
These points, already discussed in our original publication, 
are mainly due to our developing a prediction rule taking 
into account data from previous studies establishing that the 
prognosis of severe CAP depended on both baseline charac-
teristics, initial severity of infection and evolution during the 
ICU stay [7-9]. 
  In summary, the results of this prospective multicenter 
study demonstrate the performance and reproductibility of 
this prognostic prediction rule. Six predictors of mortality 
accurately predict the outcome, as early as ICU admission, 
Table 3.  Comparison of Mortality Rates in the Development and the Validation Populations* 
 
Mortality   
Development Population  Validation Population 
p Value 
Overall initial risk class  108/472 (22.9%)  148/511 (29.0%)  0.03 
I  6/153 (3.9%)  10/122 (8.2%)  0.13 
II  63/253 (24.9%)  62/272 (22.8%)  0.57 
III  39/66 (59.1%)  76/117 (65.0%)  0.43 
Adjustment in each initial risk class 
Class I 
Adjustment risk score < or = 2 points 











Adjustment risk score = 0 point 
Adjustment risk score = 1 or 2 points 
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for 50% of patients. In the remaining patients, complications 
occurring during the ICU stay are essential to accurately 
reassess final outcome. As an aid to clinicians in stratifying 
the prognosis of patients exhibiting severe CAP, this rule 
could be used for future management strategies and thera-
peutic research. 
ABBREVIATIONS 
AIDS  = Acquired Immune Deficiency Syndrome 
ARDS  = Acute respiratory distress syndrome 
CAP =  Community-acquired  pneumonia 
CURB  = Confusion, Urea nitrogen, Respiratory rate,  
     Blood pressure 
HA-LRT =  Hospital-Acquired Lower Respiratory Tract 
infection     infection 
HIV  = Human Immunodeficiency Virus 
ICU =  Intensive  Care  Unit 
MOF =  Multiple  Organ  Failure 
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